Let me bring in Dr. . John Torres who's joining us now. Okay.So, when you see this this diagnosis of CVI, is it a sign of any larger issue here. Is there any test that the White House didn't run that you think they should have. So, the chronic venous insufficiency itself is not a sign of anything.It is a benign condition like was mentioned earlier, but the causes behind it could be an issue and that's what they need to check. They did check some of them because deep vein thrombosis, that blood clot in the l ...

Core Insights - BD (Becton, Dickinson and Company) is initiating a patient data registry for the Rotarex™ Atherectomy System to evaluate real-world outcomes for patients with peripheral artery disease (PAD) [1][2]. Group 1: Registry Details - The registry, named "XTRACT," is a prospective, multi-center, single-arm, post-market study aimed at assessing the clinical performance of the Rotarex™ Atherectomy System in treating U.S. patients with PAD lesions [3]. - The XTRACT Registry will enroll up to 600 patients across approximately 100 clinical sites in the United States, with the first patient expected to be enrolled later this year [3]. - Clinical follow-up evaluations will be conducted at 30 days, 6 months, and 12 months post-procedure to assess safety and effectiveness [3]. Group 2: Clinical Significance - The registry aims to provide valuable data to support clinical decision-making and enhance patient outcomes in managing PAD [4]. - The Rotarex™ Atherectomy System is designed to efficiently remove plaque and thrombus in peripheral arteries, serving dual purposes as both an atherectomy and thrombectomy device [4]. - The XTRACT Registry is the first comprehensive registry focused on real-world applications of the Rotarex™ System, highlighting BD's commitment to optimizing treatment strategies in collaboration with leading physicians [5]. Group 3: Industry Context - PAD affects over 21 million Americans and more than 200 million people globally, posing risks of cardiovascular complications and lower limb amputation [5]. - BD's initiative reflects its ongoing commitment to innovative technological development and evidence-based research to support physicians and improve patient outcomes [5].